In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.
The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more. Comprehensive and cutting-edge, Molecular Targeting in Oncology is an essential reference for those working in the field.
Author(s): Chad D. Knights PhD, Richard G. Pestell MBBS, MD, PhD, FRACP (auth.), Howard L. Kaufman, Scott Wadler, Karen Antman (eds.)
Series: Cancer Drug Discovery and Development
Edition: 1
Publisher: Humana Press
Year: 2008
Language: English
Pages: 728
Tags: Cancer Research; Oncology; Pharmacology/Toxicology; Medicinal Chemistry
Front Matter....Pages I-XIV
Front Matter....Pages 1-1
The Cell Cycle....Pages 3-32
mTOR....Pages 33-53
Ras/Raf/MEK Inhibitors....Pages 55-73
17-AAG....Pages 75-95
The Cancer Epigenome....Pages 97-113
Front Matter....Pages 115-115
Molecular Targeting in Upper Gastrointestinal Malignancies....Pages 117-131
Molecular Targeting of Colorectal Cancer....Pages 133-163
Molecular Targeting in Hepatocellular Carcinoma....Pages 165-210
Molecularly Targeted Therapy in Pancreatic Cancer....Pages 211-226
Untargeted Use of Targeted Therapy....Pages 227-240
Renal Cell Carcinoma....Pages 241-261
Targeted Therapies for Prostate Cancer....Pages 263-290
Molecular Targets in Ovarian Cancer and Endometrial Cancer....Pages 291-308
Targeted Therapy For Breast Cancer....Pages 309-342
Melanoma....Pages 343-367
Front Matter....Pages 369-369
Antibody Therapy of Cancer....Pages 371-412
Nucleic Acid Therapies for Cancer Treatment....Pages 413-429
Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy....Pages 431-445
Vaccines as Targeted Cancer Therapy....Pages 447-469
Cytokine-Based Therapy for Cancer....Pages 471-507
Front Matter....Pages 369-369
Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment....Pages 509-541
Front Matter....Pages 543-543
Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations....Pages 545-558
Development of a Targeted Treatment for Cancer....Pages 559-571
VEGF Inhibition for Cancer Therapy....Pages 573-584
Somatostatin Analogue Therapy....Pages 585-637
Front Matter....Pages 639-639
Patient Selection for Rational Development of Novel Anticancer Agents....Pages 641-648
Clinical Trial Design with Targeted Agents....Pages 649-655
How to Define Treatment Success or Failure if Tumors Do Not Shrink....Pages 657-674
Molecular Imaging in Oncology....Pages 675-691
Combinations of Molecular-Targeted Therapies....Pages 693-705
Preclinical Development of Molecularly Targeted Agents in Oncology....Pages 707-722
Back Matter....Pages 723-728
